Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Materials Select Sector SPDR Fund — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 7.6× Materials Select Sector SPDR Fund's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| TAK | XLB | |
|---|---|---|
Market Cap | $58.74B | $7.73B |
Volume | 3,110,994 | 13,681,146 |
Sector | Health | — |
52-Week High | $19.05 | $53.67 |
52-Week Low | $13.23 | $42.23 |
Typical Hold Time | 1 Days | 70 Days |
Enterprise Value | $86.65B | — |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLB trades at $49.43, up 0.92% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent news highlights materials as a potential 'anti-AI' play but questions near-term valuation after recent rebounds.
Outlook remains cautious given technical weakness and sector cyclicality. Investment opportunity exists for long-term infrastructure exposure, but risks include overconcentration in chemicals and potential earnings volatility. Current levels near support at $49 require monitoring for breakdown confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
